drugset / Trial / NCT06499285

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285

Phase 3 Recruiting 225 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Timeline

Start
2025-05-06
Primary completion
2028-05-01
Completion
2032-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Elritercept Protein / enzyme biologic Subcutaneous